Not yet reviewed — this article is pending editorial review by Lyrea.
Citation noticeOur citation system is being overhauled
References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.
Fasoracetam
Fasoracetam is an experimental drug of the racetam group, a derivative of pyroglutamic acid, developed in the late 1980s by scientists at the Japanese pharmaceutical company Nippon Shinyaku. Marketed as a putative nootropic, it was brought through Phase 3 clinical trials for vascular dementia and abandoned for lack of efficacy, and was never marketed. It was later repurposed for ADHD and other indications with disappointing results.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Duration
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
Fasoracetam is an experimental racetam that was never marketed, and the available material describes it in pharmacological and clinical terms rather than through documented subjective experience. Clinical trials for cognitive impairment in dementia and for ADHD failed to demonstrate statistically significant efficacy. No first-person accounts of its subjective effects are present in the available sources.
Pharmacology
Pharmacodynamics
Fasoracetam appears to modulate and stimulate all three groups of metabotropic glutamate receptors (mGluRs). It also shows a form of GABA(B) antagonistic action, reversing memory impairment produced by the GABA(B) agonist baclofen and inhibiting baclofen-induced suppression of cyclic AMP formation, with repeated dosing indicated to up-regulate GABA(B) receptors. It has additionally been shown to reverse high-affinity choline uptake induced by electrolytic lesions of the basal forebrain and by pentobarbital anesthesia. Indications of antidepressant activity have been described as isolated, with no effect on monoamine uptake or central monoaminergic transmission and no action at B-adrenoceptors or 5-HT2 receptors.
Pharmacokinetics
Fasoracetam is orally bioavailable and is excreted mostly unchanged in the urine.
Interactions
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Harm Potential
History & Culture
Fasoracetam was developed in the late 1980s by scientists at the Japanese pharmaceutical company Nippon Shinyaku, who originally pursued it as a treatment for cognitive impairment related to dementia. The compound advanced as far as Phase 3 clinical trials for vascular dementia before Nippon…
Legality
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass reviewPending
Not yet reviewed — this article is pending editorial review by Lyrea.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Fasoracetam article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.